February 25, 2011 02:32 ET

DSM - proposed appointment to the Managing Board of Directors

HEERLEN, NETHERLANDS--(Marketwire - February 25, 2011) - The Supervisory Board of Royal DSM is pleased to announce that it will propose to the Annual General Meeting of Shareholders on 28 April 2011 to appoint Mr. Stefan Doboczky to the Managing Board of DSM with responsibility for DSM's Pharma cluster as well as the regional responsibility of DSM's activities in Asia, with effect from 1 May 2011.

Mr. Doboczky will operate from two office locations, in the Netherlands and in Asia in line with the further internationalization of DSM, as set out in the latest DSM strategy announced in September 2010.

Stefan Doboczky (1967), an Austrian national is at present President of the Business Group DSM Anti-Infectives. He has built a strong track record within the DSM Pharma cluster and has particular experience with business development in high growth economies, including Asia. Before joining DSM in 1998, Mr. Doboczky worked at ARCO Chemicals in Austria and the UK.

In DSM Mr. Doboczky held several senior positions in DSM Pharmaceutical Products, before he became Vice President and Business Unit Director China for DSM Anti-Infectives based in Beijing in 2006. In 2009 he became the President of DSM Anti-Infectives.

Mr. Doboczky studied at the Technical University of Vienna, Austria and he holds a Master in Chemistry and a PhD in Natural and Technical Sciences as well as an MBA from IMD in Lausanne.

In view of the ongoing formation of the joint venture between DSM Anti-Infectives and Sinochem, Mr. Doboczky will for the time being also continue in his position as President DSM Anti-Infectives.

DSM - Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about EUR 9 billion. The company is listed on NYSE Euronext. More information can be found at

Press release-pdf:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE


Contact Information

  • For more information:

    DSM Corporate Communications
    Herman Betten
    tel. +31 (0) 45 5782017
    fax +31 (0) 45 5740680
    e-mail Email Contact

    DSM Investor Relations
    Hans Vossen
    tel. +31 (0) 45 5782864
    fax +31 (0) 10 4590275
    e-mail Email Contact